Methods for use in modulating miR-122a
Methods are provided for the treatment of cardiovascular or metabolic diseases characterized by elevated serum total cholesterol, elevated serum LDL-cholesterol, or elevated serum triglycerides, through the administration of an oligomeric compound which modulates the levels or activity of miR-122a. Further provided are methods for reducing hepatic steatosis or liver tissue triglyceride accumulation through the administration of an oligomeric compound which modulates the levels or activity of miR-122a. Such methods employ oligomeric compounds which hybridize with or sterically interfere with nucleic acid molecules comprising or encoding miR-122a. Such oligomeric compounds may include one or more modifications thereon, which may improve the activity, stability, or nuclease resistance of the oligomeric compound. These modified oligomeric compounds are used as single compounds or in compositions, including pharmaceutical compositions, to modulate or mimic the targeted nucleic acid comprising or encoding miR-122a.
1. A method of lowering serum cholesterol levels in an animal comprising
a) selecting an animal having elevated serum cholesterol levels; and
b) administering to the animal a therapeutically effective amount of an antisense compound having at least 90% nucleobase sequence complementarity to a miR-122a nucleic acid, thereby lowering serum cholesterol levels.
2. The method of claim 1 , comprising lowering serum LDL-cholesterol.
3. The method of claim 1 , wherein the antisense compound is 21 to 23 nucleosides in length.
4. The method of claim 1 , wherein the antisense compound is fully complementary to a miR-122a target nucleic acid.
5. The method of claim 3 , wherein the antisense compound comprises a plurality of 2′-sugar modified nucleosides.
6. The method of claim 5 , wherein the antisense compound further comprises at least one bicyclic sugar modified nucleoside.
7. The method of claim 4 , wherein the antisense compound comprises the nucleobase sequence of SEQ ID NO: 1.
8. The method of claim 7 , wherein the antisense compound consists of the nucleobase sequence of SEQ ID NO: 2.
9. The method of claim 8 , wherein the antisense compound is uniformly comprised of 2′-MOE sugar modified nucleosides.
10. The method of claim 9 , wherein the antisense compound comprises at least one phosphorothioate internucleoside linkage.
11. The method of claim 9 , wherein the antisense compound comprises at least one 5-methylcytosine.
12. The method of claim 1 , wherein the antisense compound is an antisense oligonucleotide.
13. The method of claim 1 , wherein the antisense compound is an antisense oligonucleotide 15 to 30 linked nucleosides in length.
14. The method of claim 1 , wherein the antisense compound is an antisense oligonucleotide 17 to 25 linked nucleosides in length.
15. The method of claim 1 , wherein the animal has a disease or disorder selected from diabetes, obesity, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hyperfattyacidemia, nonalcoholic fatty liver disease, non alcoholic steatohepatitis, and metabolic syndrome.
16. The method of claim 1 , wherein the antisense compound comprises at least one bicyclic sugar modification.
17. The method of claim 16 , wherein the bicyclic sugar modification is LNA.
18. The method of claim 1 , wherein the animal is a human.
19. A method comprising administering to an animal having elevated serum cholesterol an antisense compound having at least 90% nucleobase sequence complementarity to a miR-122a nucleic acid, thereby lowering serum cholesterol in the animal.
20. The method of claim 19 , wherein the antisense compound is 15 to 30nucleosides in length.
21. The method of claim 19 , wherein the antisense compound is 21 to 23nucleosides in length.
22. The method of claim 19 , wherein the antisense compound is 17 to25nucleosides in length.
23. The method of claim 19 , wherein the antisense compound is fully complementary to a miR-122a target nucleic acid.
24. The method of claim 19 , wherein the antisense compound comprises a plurality of 2′-sugar modified nucleosides.
25. The method of claim 19 , wherein the antisense compound comprises at least one bicyclic sugar modification.
26. The method of claim 25 , wherein the bicyclic sugar modification is LNA.
27. The method of claim 19 , wherein the antisense compound comprises the nucleobase sequence of SEQ ID NO: 1.
28. The method of claim 19 , wherein the antisense compound consists of the nucleobase sequence of SEQ ID NO: 2.
29. The method of claim 19 , wherein the antisense compound is uniformly comprised of 2′-MOE sugar modified nucleosides.
30. The method of claim 19 , wherein the antisense compound comprises at least one phosphorothioate internucleoside linkage.
31. The method of claim 19 , wherein the antisense compound comprises at least one 5-methylcytosine.
32. The method of claim 19 , wherein the antisense compound is an antisense oligonucleotide.
33. The method of claim 19 , wherein the animal is a human.
34. The method of claim 12 , wherein the antisense oligonucleotide consists of the nucleobase sequence of SEQ ID NO:2, each nucleoside is a 2′—O-methoxyethyl nucleoside, each linkage is a phosphorothioate linkage, and each cytosine is a 5-methyl cytosine.
35. The method of claim 32 , wherein the antisense oligonucleotide consists of the nucleobase sequence of SEQ ID NO:2, each nucleoside is a 2′—O-methoxyethyl nucleoside, each linkage is a phosphorothioate linkage, and each cytosine is a 5-methyl cytosine.
36. The method of claim 4 , wherein the miR-122a nucleic acid comprises SEQ ID NO:3.
37. The method of claim 23 , wherein the miR-122a nucleic acid comprises SEQ ID NO:3.